BiotechTube
Pharmacelera

Pharmacelera

Barcelona, Spain· Est.
pharmacelera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6M

Overview

Pharmacelera is a Barcelona-based computational drug discovery company offering a dual business model of proprietary software and contract research services. Its core technology platform combines quantum mechanics, AI/machine learning, and high-performance computing to perform ultra-large virtual screening using advanced 3D molecular field descriptors, aiming to uncover novel chemical matter with high diversity. The company targets the early, pre-clinical stages of drug discovery, helping clients de-risk projects and identify high-quality hits more efficiently. As a private company, it serves a global clientele ranging from small biotechs to large pharmaceutical R&D departments.

AI / Machine LearningSmall Molecules

Technology Platform

Proprietary Computer-Aided Drug Design (CADD) software suite integrating Quantum-Mechanics (QM) algorithms, Machine Learning/AI, and High-Performance Computing (HPC) for ultra-large virtual screening using 3D molecular field descriptors and 3D-QSAR modeling.

Funding History

2
Total raised:$6M
Series A$4.5M
Seed$1.5M

Opportunities

The growing pressure to improve pharmaceutical R&D productivity and reduce costs creates strong demand for efficient, computational-first discovery approaches.
The rise of AI in drug discovery presents a major trend that Pharmacelera can leverage, and its hybrid software-and-services model allows it to address both large pharma and capital-efficient biotech clients.

Risk Factors

Pharmacelera faces intense competition from other computational chemistry and AI-driven drug discovery companies.
Its success depends on continuous technological validation through client molecules advancing in development, and its service-based revenue may be less scalable than pure software sales.

Competitive Landscape

Pharmacelera competes in the computational drug discovery space against public companies like Schrödinger (SDGR), numerous AI-native biotechs (e.g., Exscientia, Recursion, Atomwise), and established software vendors (e.g., OpenEye, BIOVIA). Its differentiation hinges on the claimed accuracy of its QM-based 3D field descriptors and its integrated platform for ultra-large library screening.

More companies in AI / Machine Learning →More companies in Spain →